774 related articles for article (PubMed ID: 16790322)
1. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
2. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
3. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
4. [Estrogen, SERM].
Hayashi T
Nihon Rinsho; 2011 Jul; 69(7):1270-4. PubMed ID: 21774370
[TBL] [Abstract][Full Text] [Related]
5. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
6. [Next generation selective estrogen receptor modulators].
Chaki O
Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
Palacios S
Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824
[TBL] [Abstract][Full Text] [Related]
8. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
Doran PM; Riggs BL; Atkinson EJ; Khosla S
J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
[TBL] [Abstract][Full Text] [Related]
9. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
10. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
11. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis].
Lamy O; Krieg MA
Rev Med Suisse Romande; 2002 Aug; 122(8):377-81. PubMed ID: 12357730
[TBL] [Abstract][Full Text] [Related]
12. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
Ohta H
Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen receptor modulators and postmenopausal health.
Roe EB; Chiu KM; Arnaud CD
Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
[TBL] [Abstract][Full Text] [Related]
14. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis: a review and its dental implications.
Mattson JS; Cerutis DR; Parrish LC
Compend Contin Educ Dent; 2002 Nov; 23(11):1001-4, 1006, 1008 passim; quiz 1014. PubMed ID: 12526189
[TBL] [Abstract][Full Text] [Related]
16. New possibilities for diagnosis and treatment of osteoporosis.
Miller PD
Int J Fertil Womens Med; 2001; 46(4):215-21. PubMed ID: 11563832
[TBL] [Abstract][Full Text] [Related]
17. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
[TBL] [Abstract][Full Text] [Related]
18. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
19. [Effects of SERMs on bone health. Changes in bone metabolism in cases of gender identity disorder].
Miyajima T
Clin Calcium; 2010 Mar; 20(3):380-7. PubMed ID: 20190368
[TBL] [Abstract][Full Text] [Related]
20. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
